Trial Profile

A phase 3 head-to-head study of NXT-007 with Hemlibra (Emicizumab)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emicizumab (Primary) ; NXT 007 (Primary)
Indications Haemophilia A
Focus Registrational; Therapeutic Use

Most Recent Events

27 Jun 2025 New trial record
23 Jun 2025 According to Roche media release, There are also three phase III studies currently planned for 2026 including a phase III head-to-head study with Hemlibra.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com